Develops a transcatheter aortic valve system and supplies engineered tissue to medical-device companies for heart-valve procedures.
10-K for FY2025, filed Feb 26, 2026Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to…View ↗
Our DurAVR® THV is a novel transcatheter aortic valve designed in collaboration with the world’s leading interventional cardiologists and…View ↗
On August 30, 2017, and as further amended, we entered into a supply and license agreement (as amended, the “4C Agreement”) with 4C Medical…View ↗
Customers buy regenerative tissue products directly, with sales occurring when goods are delivered; contracts typically have no significant unusual payment terms beyond 30 days.
10-K for FY2025, filed Feb 26, 2026
$1.9M
10-K for FY2025, filed Feb 26, 2026
$1.9M ↗
Medical-device maker 4C buys ADAPT tissue for its devices, while distributor LeMaitre bought CardioCel and VascuCel products under a manufacturing and supply arrangement. The company describes its sales as direct product sales.
10-K for FY2025, filed Feb 26, 2026We derive revenue from the sale of regenerative tissue products. Such sales have historically been made principally to 4C and to LeMaitre…View ↗
The Company generates its revenue from direct product sales and typically does not have any significant unusual payment terms beyond 30…View ↗
On August 30, 2017, and as further amended, we entered into a supply and license agreement (as amended, the “4C Agreement”) with 4C Medical…View ↗
No. It lost $94.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$26.8MView ↗
8-K, filed Sep 8, 2026
Appointment of Chief Financial OfficerView ↗
Competes with Edwards Lifesciences and Medtronic
10-K for FY2025, filed Feb 26, 2026We compete in the cardiovascular device market, and in particular the TAVR market. These markets are characterized by rapid change…View ↗
Loading...